Successful treatment of relapsed ménière's disease using selective serotonin reuptake inhibitors

A report of three cases

Fumiyuki Goto, Tomoko Tsutsumi, Kaoru Ogawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patients with Ménière's disease who have relapsed following endolymphatic sac surgery (EDS) or intratympanic gentamicin injection are occasionally treated with intratympanic gentamicin injections or revision surgery. However, there is a potential link between Ménière's disease and anxiety or depression. The use of serotonin selective reuptake inhibitors (SSRIs) is likely be beneficial in the treatment of patients with Ménière's disease. The aim of this report is to describe the benefits of SSRIs in patients with relapsed Meniere's disease. Over the course of two years, three patients were treated for symptoms associated with Ménière's disease with an SSRI (sertraline), with the complete resolution, or significant improvement, of symptoms. In these cases, the SSRI may have treated the associated morbidity and not Ménière's disease itself. Ménière's disease that appears to be resistant to typical otological treatment may not be just Ménière's disease. Ménière's disease may co-exist with three other conditions that are able to cause vestibular symptoms and respond to SSRIs: migraine-associated vertigo (MAV), panic disorders and chronic subjective dizziness (CSD).

Original languageEnglish
Pages (from-to)488-490
Number of pages3
JournalExperimental and Therapeutic Medicine
Volume7
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Serotonin Uptake Inhibitors
Therapeutics
Gentamicins
Endolymphatic Sac
Sertraline
Meniere Disease
Panic Disorder
Vertigo
Dizziness
Migraine Disorders
Reoperation
Anxiety
Depression
Morbidity

Keywords

  • Ménière's disease
  • Serotonin selective reuptake inhibitors

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Immunology and Microbiology (miscellaneous)

Cite this

Successful treatment of relapsed ménière's disease using selective serotonin reuptake inhibitors : A report of three cases. / Goto, Fumiyuki; Tsutsumi, Tomoko; Ogawa, Kaoru.

In: Experimental and Therapeutic Medicine, Vol. 7, No. 2, 2014, p. 488-490.

Research output: Contribution to journalArticle

@article{34f767c4f9774e08bd5b5676fba81d68,
title = "Successful treatment of relapsed m{\'e}ni{\`e}re's disease using selective serotonin reuptake inhibitors: A report of three cases",
abstract = "Patients with M{\'e}ni{\`e}re's disease who have relapsed following endolymphatic sac surgery (EDS) or intratympanic gentamicin injection are occasionally treated with intratympanic gentamicin injections or revision surgery. However, there is a potential link between M{\'e}ni{\`e}re's disease and anxiety or depression. The use of serotonin selective reuptake inhibitors (SSRIs) is likely be beneficial in the treatment of patients with M{\'e}ni{\`e}re's disease. The aim of this report is to describe the benefits of SSRIs in patients with relapsed Meniere's disease. Over the course of two years, three patients were treated for symptoms associated with M{\'e}ni{\`e}re's disease with an SSRI (sertraline), with the complete resolution, or significant improvement, of symptoms. In these cases, the SSRI may have treated the associated morbidity and not M{\'e}ni{\`e}re's disease itself. M{\'e}ni{\`e}re's disease that appears to be resistant to typical otological treatment may not be just M{\'e}ni{\`e}re's disease. M{\'e}ni{\`e}re's disease may co-exist with three other conditions that are able to cause vestibular symptoms and respond to SSRIs: migraine-associated vertigo (MAV), panic disorders and chronic subjective dizziness (CSD).",
keywords = "M{\'e}ni{\`e}re's disease, Serotonin selective reuptake inhibitors",
author = "Fumiyuki Goto and Tomoko Tsutsumi and Kaoru Ogawa",
year = "2014",
doi = "10.3892/etm.2013.1412",
language = "English",
volume = "7",
pages = "488--490",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Successful treatment of relapsed ménière's disease using selective serotonin reuptake inhibitors

T2 - A report of three cases

AU - Goto, Fumiyuki

AU - Tsutsumi, Tomoko

AU - Ogawa, Kaoru

PY - 2014

Y1 - 2014

N2 - Patients with Ménière's disease who have relapsed following endolymphatic sac surgery (EDS) or intratympanic gentamicin injection are occasionally treated with intratympanic gentamicin injections or revision surgery. However, there is a potential link between Ménière's disease and anxiety or depression. The use of serotonin selective reuptake inhibitors (SSRIs) is likely be beneficial in the treatment of patients with Ménière's disease. The aim of this report is to describe the benefits of SSRIs in patients with relapsed Meniere's disease. Over the course of two years, three patients were treated for symptoms associated with Ménière's disease with an SSRI (sertraline), with the complete resolution, or significant improvement, of symptoms. In these cases, the SSRI may have treated the associated morbidity and not Ménière's disease itself. Ménière's disease that appears to be resistant to typical otological treatment may not be just Ménière's disease. Ménière's disease may co-exist with three other conditions that are able to cause vestibular symptoms and respond to SSRIs: migraine-associated vertigo (MAV), panic disorders and chronic subjective dizziness (CSD).

AB - Patients with Ménière's disease who have relapsed following endolymphatic sac surgery (EDS) or intratympanic gentamicin injection are occasionally treated with intratympanic gentamicin injections or revision surgery. However, there is a potential link between Ménière's disease and anxiety or depression. The use of serotonin selective reuptake inhibitors (SSRIs) is likely be beneficial in the treatment of patients with Ménière's disease. The aim of this report is to describe the benefits of SSRIs in patients with relapsed Meniere's disease. Over the course of two years, three patients were treated for symptoms associated with Ménière's disease with an SSRI (sertraline), with the complete resolution, or significant improvement, of symptoms. In these cases, the SSRI may have treated the associated morbidity and not Ménière's disease itself. Ménière's disease that appears to be resistant to typical otological treatment may not be just Ménière's disease. Ménière's disease may co-exist with three other conditions that are able to cause vestibular symptoms and respond to SSRIs: migraine-associated vertigo (MAV), panic disorders and chronic subjective dizziness (CSD).

KW - Ménière's disease

KW - Serotonin selective reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84890475285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890475285&partnerID=8YFLogxK

U2 - 10.3892/etm.2013.1412

DO - 10.3892/etm.2013.1412

M3 - Article

VL - 7

SP - 488

EP - 490

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 2

ER -